Results 81 to 90 of about 1,725,195 (297)

Diversity in the media: talk is cheap, what we need is action [PDF]

open access: yes, 2014
Marcus Ryder is the Chair of the Royal Television Society Diversity Committee, and Head of Current Affairs BBC Scotland. He recently organised the first political hustings on media diversity between the three main Westminster political parties on how ...
Ryder, Marcus
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Influence of Two Root Media and Three Vermicompost Amendments on Bacterial Communities in a Greenhouse Container Garden Model System

open access: yesMicroorganisms
The aim of this study was to determine the impact of two root media and three vermicompost amendments on the root zone bacterial communities and harvest mass of lettuce grown in a greenhouse container garden model system.
Sihan Bu   +6 more
doaj   +1 more source

MEDIA SIBER, APARAT, DAN PEMBERITAAN KEBERAGAMAN

open access: yesJurnal Aspikom, 2019
The up and down of relations between the government and the media have been the topic of various studies for decades. Historically, relations between the two parties were characterized by unequal power relations.
Riris Loisa   +3 more
doaj   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

Media and Diversity

open access: yesCalenda, 2013
InMedia, a blind peer-reviewed on-line journal dedicated to the study of the media and media representations in the English-speaking world, welcomes proposals for its fourth issue whose themed section will be dedicated to Media and Diversity. As InMedia provides a multidisciplinary approach and comparative perspectives, contributions are welcome from ...
openaire   +1 more source

Diversity in the Media: a Chart Book for Selected Industries [PDF]

open access: yes, 2004
[Excerpt] This chart book responds to the public’s request for data regarding diversity in employment among some of the key media industries in the nation.
Equal Employment Opportunity Commission, U.S.
core   +2 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy